Palani Palaniappan, Ph.D., has more than twenty-five years of pharmaceutical experience. He currently serves as Senior Vice President and Head of Global Technical Operations at Sarepta Therapeutics, Inc., where he leads the Company’s Technical Operations team responsible for all stages of development from research through commercial. His team focuses on the development of Sarepta’s RNA and gene therapy portfolios.
Prior to joining Sarepta, Dr. Palaniappan held leadership positions of increasing responsibility at Takeda Pharmaceuticals, most recently leading biologics and new modality development. Before Takeda, he spent a number of years each at Millennium Pharmaceuticals, Biogen, Gilead Sciences and Par Pharmaceuticals. Over the course of his career, he has contributed to the development and commercialization of over ten products in small molecule, biologics, antibody-drug conjugate, and stem cell modalities.
Dr. Palaniappan has completed executive leadership education at the University of Oxford and Instead. He received his Ph.D. in chemistry from the Indian Institute of Technology, Kanpur and completed his post-doctoral studies in biochemistry and biophysics at the University of California, Riverside and Virginia Commonwealth University. He holds an MS in chemistry and a BS in chemistry, physics, and mathematics from Annamalai University.